Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)

Introduction: Glycemic control is important to avoid diabetes complications in individuals with cancer. There is no evidence for HbA1c and fructosamine as reliable biomarkers in these conditions. There are particularities in caring for patients with diabetes and cancer that can alter these biomarker...

ver descrição completa

Detalhes bibliográficos
Autores: Toyoshima, Marcos Tadashi Kakitani, Cukier, Priscilla, Damascena, Aline Santos, Batista, Rafael Loch, Correa, Fernanda de Azevedo, Kawahara, Eduardo Zanatta, Minanni, Carlos André, Hoff, Ana O., Nery, Marcia
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2023
País:Brasil
Recursos:Universidade de São Paulo (USP)
Repositório:Clinics
Idioma:inglês
OAI Identifier:oai:revistas.usp.br:article/214038
Acesso em linha:https://www.revistas.usp.br/clinics/article/view/214038
Access Level:Acceso aberto
Palavra-chave:Chemotherapy
Glucocorticoids
Cancer
Glycemic control
Fructosamine
HbA1c
id BR_9152604eb2a7f29ea0526e3d1dd478bb
oai_identifier_str oai:revistas.usp.br:article/214038
network_acronym_str BR
network_name_str Brasil
repository_id_str
spelling Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)ChemotherapyGlucocorticoidsCancerGlycemic controlFructosamineHbA1cIntroduction: Glycemic control is important to avoid diabetes complications in individuals with cancer. There is no evidence for HbA1c and fructosamine as reliable biomarkers in these conditions. There are particularities in caring for patients with diabetes and cancer that can alter these biomarkers. Objective: The aim of this study was to evaluate HbA1c and fructosamine as glycemic biomarkers in people with type 2 diabetes and cancer, undergoing clinical or surgical oncological treatment. Methods: The authors conducted a single-center, retrospective analysis with people who have cancer and diabetes. Comparison of glycemic biomarkers (HbA1c, fructosamine, and Self-Monitoring of Blood Glucose [SMBG]) was performed including evaluation in individuals undergoing chemotherapy, using glucocorticoids, with anemia, hypoproteinemia or with reduced estimated Glomerular Filtration Rate (eGFR). Results: There was a strong positive correlation between fructosamine and HbA1c (n = 318, r = 0.66, p < 0.001) in people with diabetes and cancer even in those under chemotherapy (n = 101, r = 0.61, p < 0.001) or using glucocorticoids (n = 96, r = 0.67, p<0.001). There was a strong correlation between HbA1c and fructosamine in subjects with anemia (n = 111, r = 0.66, p < 0.001), hypoproteinemia (n = 54, r = 0.67, p < 0.001), or with eGFR ≥ 60 mL/min/1.73 m2 (n = 189, r = 0.70, p < 0.001), and moderate correlation with hypoalbuminemia (n = 21, r = 0.54, p = 0.001) and with reduced eGFR (n = 67, r = 0.57, p < 0.001). The correlations between fructosamine and HbA1c with SMBG were moderate (n = 164, r = 0.49, p < 0.001; n = 111, r = 0.55, p < 0.001, respectively), strong in subjects undergoing chemotherapy, with hypoalbuminemia or hypoproteinemia, and at least moderate, if eGFR < 60 mL/min/1.73 m2 or with anemia. Conclusions: Fructosamine and HbA1c can be used as glycemic biomarkers in people with diabetes and cancer, even in those with anemia, hypoproteinemia, or undergoing chemotherapy.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2023-06-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21403810.1016/j.clinsp.2023.100240Clinics; Vol. 78 (2023); 100240Clinics; v. 78 (2023); 100240Clinics; Vol. 78 (2023); 1002401980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/214038/196273Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessToyoshima, Marcos Tadashi KakitaniCukier, PriscillaDamascena, Aline SantosBatista, Rafael LochCorrea, Fernanda de AzevedoKawahara, Eduardo ZanattaMinanni, Carlos AndréHoff, Ana O.Nery, Marcia2023-07-06T13:05:40Zoai:revistas.usp.br:article/214038Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:05:40Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
title Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
spellingShingle Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
Toyoshima, Marcos Tadashi Kakitani
Chemotherapy
Glucocorticoids
Cancer
Glycemic control
Fructosamine
HbA1c
title_short Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
title_full Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
title_fullStr Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
title_full_unstemmed Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
title_sort Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
dc.creator.none.fl_str_mv Toyoshima, Marcos Tadashi Kakitani
Cukier, Priscilla
Damascena, Aline Santos
Batista, Rafael Loch
Correa, Fernanda de Azevedo
Kawahara, Eduardo Zanatta
Minanni, Carlos André
Hoff, Ana O.
Nery, Marcia
author Toyoshima, Marcos Tadashi Kakitani
author_facet Toyoshima, Marcos Tadashi Kakitani
Cukier, Priscilla
Damascena, Aline Santos
Batista, Rafael Loch
Correa, Fernanda de Azevedo
Kawahara, Eduardo Zanatta
Minanni, Carlos André
Hoff, Ana O.
Nery, Marcia
author_role author
author2 Cukier, Priscilla
Damascena, Aline Santos
Batista, Rafael Loch
Correa, Fernanda de Azevedo
Kawahara, Eduardo Zanatta
Minanni, Carlos André
Hoff, Ana O.
Nery, Marcia
author2_role author
author
author
author
author
author
author
author
dc.subject.por.fl_str_mv Chemotherapy
Glucocorticoids
Cancer
Glycemic control
Fructosamine
HbA1c
topic Chemotherapy
Glucocorticoids
Cancer
Glycemic control
Fructosamine
HbA1c
description Introduction: Glycemic control is important to avoid diabetes complications in individuals with cancer. There is no evidence for HbA1c and fructosamine as reliable biomarkers in these conditions. There are particularities in caring for patients with diabetes and cancer that can alter these biomarkers. Objective: The aim of this study was to evaluate HbA1c and fructosamine as glycemic biomarkers in people with type 2 diabetes and cancer, undergoing clinical or surgical oncological treatment. Methods: The authors conducted a single-center, retrospective analysis with people who have cancer and diabetes. Comparison of glycemic biomarkers (HbA1c, fructosamine, and Self-Monitoring of Blood Glucose [SMBG]) was performed including evaluation in individuals undergoing chemotherapy, using glucocorticoids, with anemia, hypoproteinemia or with reduced estimated Glomerular Filtration Rate (eGFR). Results: There was a strong positive correlation between fructosamine and HbA1c (n = 318, r = 0.66, p < 0.001) in people with diabetes and cancer even in those under chemotherapy (n = 101, r = 0.61, p < 0.001) or using glucocorticoids (n = 96, r = 0.67, p<0.001). There was a strong correlation between HbA1c and fructosamine in subjects with anemia (n = 111, r = 0.66, p < 0.001), hypoproteinemia (n = 54, r = 0.67, p < 0.001), or with eGFR ≥ 60 mL/min/1.73 m2 (n = 189, r = 0.70, p < 0.001), and moderate correlation with hypoalbuminemia (n = 21, r = 0.54, p = 0.001) and with reduced eGFR (n = 67, r = 0.57, p < 0.001). The correlations between fructosamine and HbA1c with SMBG were moderate (n = 164, r = 0.49, p < 0.001; n = 111, r = 0.55, p < 0.001, respectively), strong in subjects undergoing chemotherapy, with hypoalbuminemia or hypoproteinemia, and at least moderate, if eGFR < 60 mL/min/1.73 m2 or with anemia. Conclusions: Fructosamine and HbA1c can be used as glycemic biomarkers in people with diabetes and cancer, even in those with anemia, hypoproteinemia, or undergoing chemotherapy.
publishDate 2023
dc.date.none.fl_str_mv 2023-06-28
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/214038
10.1016/j.clinsp.2023.100240
url https://www.revistas.usp.br/clinics/article/view/214038
identifier_str_mv 10.1016/j.clinsp.2023.100240
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/214038/196273
dc.rights.driver.fl_str_mv Copyright (c) 2023 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 78 (2023); 100240
Clinics; v. 78 (2023); 100240
Clinics; Vol. 78 (2023); 100240
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1853664773065932800
score 15,198674

Registros relacionados